Hormonal Contraception Market Update - Surviving the Generic Threat

Introduction

Hormonal contraception is a mature and overcrowded market, dominated by oral products, where high-levels of contraceptive efficacy are the norm. The market is worth over $4bn, the majority of which comes from the US, 2.5bn. Achieving success in this arena will depend on product differentiation, a factor that will become increasingly important as generic drugs flood into the market. 

Scope

Analysis of the current position of the oral contraceptive market leader Ortho Tri-Cyclen and contributing factors to its success. 

Strategies for survival post patent expiry including product reformulation, geographical expansion and additional / non-contraceptive indications. 

Assessment of key competitors in the market and the potential of core proprietary products against growing generic pressure. 

Report Highlights

Ortho McNeil’s strategies to survive the patent expiry of Ortho Tri-Cyclen will not be successful in the short term, leading to a loss in revenues and value of its contraception franchise. 

While oral contraceptives are expected to continue to dominate, product differentiation remains key in gaining a competitive edge in the market. Strategies are set to focus on reformulation and the pursuit of additional indications. 

Already a fragmented and poorly differentiated market, the specter of genericization and generic substitution is a growing threat to major players, particularly as managed care organizations are poised to exploit low-cost equivalents. 

Reasons to Purchase

Learn what Ortho McNeil is / should be doing to keep lost revenue to a minimum as the patent on Ortho Tri-Cyclen approaches expiry 

Assess how this key event in the oral contraceptive market will impact upon the other major players: Schering AG, Wyeth, Organon & Barr 

Publisher: Datamonitor Womens Health Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Womens_Health.html#a383